- Home
- IEX vs UTHR Comparison
IEX vs UTHR Comparison
Compare IEX & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IEX
- UTHR
- Stock Information
- Founded
- IEX 1987
- UTHR 1996
- Country
- IEX United States
- UTHR United States
- Employees
- IEX N/A
- UTHR N/A
- Industry
- IEX Fluid Controls
- UTHR Biotechnology: Pharmaceutical Preparations
- Sector
- IEX Industrials
- UTHR Health Care
- Exchange
- IEX Nasdaq
- UTHR Nasdaq
- Market Cap
- IEX 12.4B
- UTHR 13.8B
- IPO Year
- IEX 1991
- UTHR 1999
- Fundamental
- Price
- IEX $161.15
- UTHR $403.11
- Analyst Decision
- IEX Buy
- UTHR Strong Buy
- Analyst Count
- IEX 6
- UTHR 15
- Target Price
- IEX $208.83
- UTHR $449.13
- AVG Volume (30 Days)
- IEX 659.0K
- UTHR 894.2K
- Earning Date
- IEX 10-28-2025
- UTHR 10-29-2025
- Dividend Yield
- IEX 1.76%
- UTHR N/A
- EPS Growth
- IEX N/A
- UTHR 17.94
- EPS
- IEX 6.18
- UTHR 25.63
- Revenue
- IEX $3,340,800,000.00
- UTHR $3,077,800,000.00
- Revenue This Year
- IEX $6.12
- UTHR $13.89
- Revenue Next Year
- IEX $4.01
- UTHR $5.68
- P/E Ratio
- IEX $26.07
- UTHR $15.73
- Revenue Growth
- IEX 4.73
- UTHR 17.62
- 52 Week Low
- IEX $153.36
- UTHR $266.98
- 52 Week High
- IEX $238.22
- UTHR $436.95
- Technical
- Relative Strength Index (RSI)
- IEX 43.32
- UTHR 70.30
- Support Level
- IEX $159.40
- UTHR $395.00
- Resistance Level
- IEX $164.77
- UTHR $407.06
- Average True Range (ATR)
- IEX 2.88
- UTHR 13.35
- MACD
- IEX 0.08
- UTHR 4.82
- Stochastic Oscillator
- IEX 22.76
- UTHR 74.89
About IEX IDEX Corporation
Idex manufactures pumps, flow meters, valves, and fluidic systems for customers in a variety of end markets, including industrial, fire and safety, life science, and water. The firm's business is organized into three segments: fluid and metering technologies, health and science technologies, and fire and safety and diversified products. Based in Lake Forest, Illinois, Idex has manufacturing operations in over 20 countries and has over 7,000 employees. The company generated $3.3 billion in revenue in 2024.
About UTHR United Therapeutics Corporation
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.